SlideShare a Scribd company logo
1 of 1
Download to read offline
ISOLATION AND ANALYSIS OF CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA AS ENABLED BY THE VERSA.
E. Jason Abel, Jacob J. Tokar, Benjamin P. Casavant, Stephanie Thiede, Lindsay Strotman, David J. Beebe, Joshua M. Lang
University of Wisconsin Carbone Cancer Center
Acknowledgements
Process
Blood Collection Ficoll-Paque
Density Centrifugation
VERSA Isolation,
Staining, and Imaging
Clinical Data
Blood from patients with metastatic clear cell carcinoma of the
kidney were were drawn with a UW-IRB approved protocol and
their CTCs were stained and analyzed for intact nuclei (DAPI),
Carbonic Anhydrase IX and Cytokeratins. Single cells and cell
clumps were identified from patient samples.
Conclusions and Future Work
Isolation and purification of RCC cells from peripheral blood
using CAIX is possible using the VERSA platform.
Ongoing studies will be aimed at identifying CTC heterogeneity,
evaluation of DNA and RNA isolated from CTCs to provide evi-
dence of their biologic potential in the metastatic cascade.
Future studies will also investigate the potential of CTCs for
prognostic indicators beyond methods of enumeration.
Adhesion Invasion Metastases
This work was supported by a grant from the Wisconsing Partnership
Program and the DOD PCRP W81XWH-09-1-0192
Background
Metastases, not primary tumors, are the most common cause for cancer pa-
tient mortality. Circulating tumor cells are cells within the metastatic cas-
cade that are accessible by a simple blood draw, and can act as a `liquid
biopsy’for understanding tumor progression. Their enumeration has shown
prognostic relevance, however methods to integrate analyses and take
CTCs beyond enumeration have been limited.
Intravasation and Transit
Adhesion/Arrest Extravasation
CTCs
Abbreviations:
PMP - Paramagnetic ParticleCTC - Circulating Tumor Cell
PBMC - Peripheral Blood Mononuclear Cell
The VERSA:
Isolation:
bead-bound
cells of interest
Non-target cells
Magnet
2) Magnet pull
1) Add PMPs
Vertical Exclusion Based
Rare Sample Analysis
Principle:
Two aqueous solutions can be placed in adjacent
wells, and due to the relative dominance of surface
tension on the microscale, stay pinned, creating a‘vir-
tual wall’at the interface.
virtual
wall
Aqueous phases
(cell suspensions, stains, washes)
Oil phases
INTRODUCTION AND OBJECTIVES: Circulating tumor cells (CTCs) have dem-
onstrated prognostic ability in several cancers but similar studies in Renal
Cell Carcinoma (RCC) are limited because the current techniques rely on
positive selection of cells using cell surface markers rarely expressed in RCC
cells. We have designed a novel platform to permit the use of any antibody
of interest bound to paramagnetic particles (PMPs) to isolate and purify
PMP-bound cells via immiscible oil barriers. The purpose of this study was
to demonstrate and validate RCC cell isolation from blood by positive se-
lection of cells expressing carbonic anhydrase nine (CAIX).
METHODS: The Vertical Immiscible Filtration Assisted by Surface Tension
(VerIFAST) platform was designed (BC, DB, patent filed) using the relative
dominance of surface tension in the microscale to create virtual walls be-
tween oil and aqueous phases filtering contaminants in a single step, while
maintaining cell viability for further analysis. Initial experiments used
samples of whole blood spiked with known RCC cell lines (786-0). After op-
timization of technique and confirmation of capture, samples from patients
with locally advanced and metastatic RCC were evaluated.
RESULTS: Initial results demonstrate a high capture efficiency of the spiked
786-0 cells (~75% capture efficiency) and the ability to integrate intracellu-
lar staining, with successful staining of both cytokeratins and the prolifera-
tive marker, Ki-67. Patient CTCs were isolated and stained for intracellular
cytokeratins for initial patient validation.
CONCLUSIONS: Isolation and purification of RCC cells from peripheral
blood using CAIX is possible using this novel platform. Further, the ability
to perform intracellular analyses for therapeutic targets promotes the abil-
ity of the VerIFAST to act as a liquid biopsy, informing clinical decision-
making through analysis of cells directly within the metastatic cascade. On-
ngoing studies with the VerIFAST will be aimed at identifying CTC heterog-
eneity with the targets of cMet and mTOR, realizing the potential of CTCs for
prognostic indicators beyond methods of enumeration
Abstract
Vertical Cell Isolation
Vertical device orientation, featuring the long axis on the vertical instead of
horizontal axis, allows non-target cells to passively settle out of the opera-
tional path of the PMP-bound target cells
FG FM
Input
Magnet
Oil
Traverses
Wash Output
0
100
200
300
400
500
600
700
800
900
NumberofCells
PBMC
LNCaP
Purity
Traverse Number
1 2 3
77% 82%
86%
1 2 3
VERSA Device Side-View
Force
Vectors Cell Data
This allows us to capture a few cells from a large background:
0
20
40
60
80
100
5M 20M 100M
PercentRecovery
Background PBMCs
(M = million)
One cell in 20M PBMCs
target well
Variable PBMCs
PMP were bound to an antibody
specific for Carbonic Anhydrase IX.
The immortalized renal cancer cell
line, 786-O, were incubated with
CAIX-PMPs in the VERSA chip then
captured as above. We show that
capture efficiencies of 60-75% that
is dependent on cell surface expres-
sion of CAIX based on trypsiniza-
tion versus gentle cell dissociation.
Sieve-Assisted Staining
A microporous membrane is fabricated into one of the VerIFAST wells such that
fluid can be added and replaced from an adjacent well without touching the
sample, critical for rare or delicate cell samples and enabling sophisticated flu-
idic procedures in-device.
Membrane
Aspirate
Add Fluid (Wash, Fixative, etc.)
Incubate
Repeatasnecessary
Top View Side View
Fluid Exchanges
Rear
Well
Front
Well
Magnet
PMP Removal
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1 2 3 4 5
Wash Number
Normalized
NumberofCells
Loss Due to Washing
786-O Cells are then fixed, permeabilized, and stained with primary
and secondary antibodies for extra and intracellular proteins
Brightfield KI-67
Cytokeratins DAPI
Merged
MergedMerged
DAPIDAPI
Cytokeratins Total C-MET
CA IX CA IX
Total Nucleic Acid Extraction
After imaging, cells are lysed with a RIPA buffer and PMPs bound to an oligo-dT
are added to capture mRNA. An external magnetic force is applied and the
PMP-mRNA conjugates are purified into the final rear well of the chip. A high
salt buffer is then added to the sieve well to lyse nuclei. Silica beads are then
added to bind DNA. An external magnetic force is applied and the PMP-DNA
conjugates are purified into the final front well of the chip. Nucleic acids are
eluted from PMPs in a 15uL volume and used for quantitative PCR for GAPDH
and compared to a commercial Qiagen kit.
786-O cells were processed by the VERSA and mRNA extracted for gene expres-
sion analysis of a housekeeping gene, P0, HIF1, HIF2, and FIH.
Input
Live Cell
Staining
Intracellular
Staining
DNA
Purification
mRNA
Purification
1
10
100
1,000
10,000
100,000
1000 100 10 1
RelativeDNASignal
Number of Cells
Qiagen AllPrep
VERSA
1
10
100
1,000
10,000
100,000
1000 100 10 1
RelativeRNASignal
Number of Cells
Qiagen AllPrep
VERSA
DAPI
CKs
CA IX
Merged
DAPI
CKs
CA IX
Merged

More Related Content

What's hot

CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...
CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...
CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...IanTaylor50
 
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)vshidham1
 
MetaMax presentation for Skolkovo
MetaMax presentation for SkolkovoMetaMax presentation for Skolkovo
MetaMax presentation for SkolkovoMaxwellBiotech
 
Poster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionPoster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionIanTaylor50
 
US Pharma presentation on clone screen strategy for monoclonality using Solen...
US Pharma presentation on clone screen strategy for monoclonality using Solen...US Pharma presentation on clone screen strategy for monoclonality using Solen...
US Pharma presentation on clone screen strategy for monoclonality using Solen...IanTaylor50
 
Arna Andrews, CSL limited (vienna, april 2016)
Arna Andrews,  CSL limited (vienna, april 2016)Arna Andrews,  CSL limited (vienna, april 2016)
Arna Andrews, CSL limited (vienna, april 2016)IanTaylor50
 
Fluorescent Activated Cell Sorting: Diagnosis of HIV Infection
Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionFluorescent Activated Cell Sorting: Diagnosis of HIV Infection
Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionAf Ashraf
 
Lab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringLab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringstanislas547
 
Cancer in vein 2 11-2018
Cancer in vein 2 11-2018Cancer in vein 2 11-2018
Cancer in vein 2 11-2018Waheed Shouman
 
Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchmohammed4450
 
Reporter stem cells generation
Reporter stem cells generation Reporter stem cells generation
Reporter stem cells generation Stella Evelyn
 
esibio General Sales presentation August update
esibio General Sales presentation August updateesibio General Sales presentation August update
esibio General Sales presentation August updateShaun Teacher
 
Celonic presentation on VIPS - BPI Boston (Sept 2019)
Celonic presentation on VIPS - BPI Boston (Sept 2019)Celonic presentation on VIPS - BPI Boston (Sept 2019)
Celonic presentation on VIPS - BPI Boston (Sept 2019)IanTaylor50
 
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)IanTaylor50
 
Clonality report for cell metric customer launch
Clonality report for cell metric   customer launchClonality report for cell metric   customer launch
Clonality report for cell metric customer launchIanTaylor50
 
Flowcytometry
FlowcytometryFlowcytometry
FlowcytometryBadheeb
 
Nucleic acid extraction from FFPE cell blocks
Nucleic acid extraction from FFPE cell blocks Nucleic acid extraction from FFPE cell blocks
Nucleic acid extraction from FFPE cell blocks Caroline Seiler
 

What's hot (20)

CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...
CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...
CASSS Forum Poster - Enabling robist cloning method qualification in cell lin...
 
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)
01 CellBlockistry- IAC 2019 (May 6-Monday 16- 1500 to ­1800)
 
MetaMax presentation for Skolkovo
MetaMax presentation for SkolkovoMetaMax presentation for Skolkovo
MetaMax presentation for Skolkovo
 
Poster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory SubmissionPoster presentation - Documented Clonality Report for Regulatory Submission
Poster presentation - Documented Clonality Report for Regulatory Submission
 
US Pharma presentation on clone screen strategy for monoclonality using Solen...
US Pharma presentation on clone screen strategy for monoclonality using Solen...US Pharma presentation on clone screen strategy for monoclonality using Solen...
US Pharma presentation on clone screen strategy for monoclonality using Solen...
 
Arna Andrews, CSL limited (vienna, april 2016)
Arna Andrews,  CSL limited (vienna, april 2016)Arna Andrews,  CSL limited (vienna, april 2016)
Arna Andrews, CSL limited (vienna, april 2016)
 
Fluorescent Activated Cell Sorting: Diagnosis of HIV Infection
Fluorescent Activated Cell Sorting: Diagnosis of HIV InfectionFluorescent Activated Cell Sorting: Diagnosis of HIV Infection
Fluorescent Activated Cell Sorting: Diagnosis of HIV Infection
 
Lab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringLab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoring
 
Cancer in vein 2 11-2018
Cancer in vein 2 11-2018Cancer in vein 2 11-2018
Cancer in vein 2 11-2018
 
Prof.dr.moh'd sorour bch
Prof.dr.moh'd sorour bchProf.dr.moh'd sorour bch
Prof.dr.moh'd sorour bch
 
Reporter stem cells generation
Reporter stem cells generation Reporter stem cells generation
Reporter stem cells generation
 
esibio General Sales presentation August update
esibio General Sales presentation August updateesibio General Sales presentation August update
esibio General Sales presentation August update
 
Celonic presentation on VIPS - BPI Boston (Sept 2019)
Celonic presentation on VIPS - BPI Boston (Sept 2019)Celonic presentation on VIPS - BPI Boston (Sept 2019)
Celonic presentation on VIPS - BPI Boston (Sept 2019)
 
Juli Overview Sheet
Juli Overview SheetJuli Overview Sheet
Juli Overview Sheet
 
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)
Thomas Sterovsky - Polymun Scientific (Vienna Conference, April 2016)
 
Application Note: Angiogenesis
Application Note: AngiogenesisApplication Note: Angiogenesis
Application Note: Angiogenesis
 
Clonality report for cell metric customer launch
Clonality report for cell metric   customer launchClonality report for cell metric   customer launch
Clonality report for cell metric customer launch
 
Flowcytometry
FlowcytometryFlowcytometry
Flowcytometry
 
Nucleic acid extraction from FFPE cell blocks
Nucleic acid extraction from FFPE cell blocks Nucleic acid extraction from FFPE cell blocks
Nucleic acid extraction from FFPE cell blocks
 
Cancer diagnosis
Cancer diagnosisCancer diagnosis
Cancer diagnosis
 

Similar to AUA Poster 2013-final

antigen presentation machinery in ctcs (1)
antigen presentation machinery in ctcs (1)antigen presentation machinery in ctcs (1)
antigen presentation machinery in ctcs (1)Stephanie Thiede
 
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptx
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptxMOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptx
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptxAmosiRichard
 
Cell sepration and flowcytometry
Cell sepration and flowcytometryCell sepration and flowcytometry
Cell sepration and flowcytometrysafoora pordel
 
CTC Methods in comparison
CTC Methods in comparisonCTC Methods in comparison
CTC Methods in comparisonPeter Pachmann
 
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...European School of Oncology
 
Predictive biomarkers for lung cancer
Predictive biomarkers for lung cancerPredictive biomarkers for lung cancer
Predictive biomarkers for lung cancerKumar Utsav
 
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...CrimsonpublishersCancer
 
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...Quality Assistance s.a.
 
Diagnostic approach to metastatic adenocarcinoma
Diagnostic approach to metastatic adenocarcinomaDiagnostic approach to metastatic adenocarcinoma
Diagnostic approach to metastatic adenocarcinomaSivaranjini N
 
Cells undergoing morphological changes during apoptosis
Cells undergoing morphological changes during apoptosisCells undergoing morphological changes during apoptosis
Cells undergoing morphological changes during apoptosisAnimatedWorld
 
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...QIAGEN
 
FNP workshop presentation
FNP workshop presentation FNP workshop presentation
FNP workshop presentation anshusls
 
Medicon 2016 presentation
Medicon 2016 presentationMedicon 2016 presentation
Medicon 2016 presentationmadurai
 
Automation in blood banking
Automation in blood bankingAutomation in blood banking
Automation in blood bankingShreya D Prabhu
 
Radar on rcc
Radar on rccRadar on rcc
Radar on rccmadurai
 

Similar to AUA Poster 2013-final (20)

antigen presentation machinery in ctcs (1)
antigen presentation machinery in ctcs (1)antigen presentation machinery in ctcs (1)
antigen presentation machinery in ctcs (1)
 
Liquid biopsy
Liquid biopsyLiquid biopsy
Liquid biopsy
 
Nanotechnology in Cancer - Dr. Cote
Nanotechnology in Cancer - Dr. CoteNanotechnology in Cancer - Dr. Cote
Nanotechnology in Cancer - Dr. Cote
 
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptx
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptxMOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptx
MOLECULAR AND CYTOGENETIC ANALYSIS -BMLS GENERAL &HBT-1.pptx
 
Cell sepration and flowcytometry
Cell sepration and flowcytometryCell sepration and flowcytometry
Cell sepration and flowcytometry
 
Dr. Martin McIntosh: Identifying Cancer Selective Proteins Using RNA-Sequenci...
Dr. Martin McIntosh: Identifying Cancer Selective Proteins Using RNA-Sequenci...Dr. Martin McIntosh: Identifying Cancer Selective Proteins Using RNA-Sequenci...
Dr. Martin McIntosh: Identifying Cancer Selective Proteins Using RNA-Sequenci...
 
CTC Methods in comparison
CTC Methods in comparisonCTC Methods in comparison
CTC Methods in comparison
 
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...
MCO 2011 - Slide 35 - F. Blackhall - Spotlight session - Circulating tumour c...
 
KO poster 8:13
KO poster 8:13KO poster 8:13
KO poster 8:13
 
Predictive biomarkers for lung cancer
Predictive biomarkers for lung cancerPredictive biomarkers for lung cancer
Predictive biomarkers for lung cancer
 
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...
The Acoustic Technology for Ctcs Isolation in Blood: Low-Cost Devices_Crimson...
 
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
WEBINAR Characterisation of human pluripotent stem cells (ESCs and IPSC) and ...
 
Diagnostic approach to metastatic adenocarcinoma
Diagnostic approach to metastatic adenocarcinomaDiagnostic approach to metastatic adenocarcinoma
Diagnostic approach to metastatic adenocarcinoma
 
Cells undergoing morphological changes during apoptosis
Cells undergoing morphological changes during apoptosisCells undergoing morphological changes during apoptosis
Cells undergoing morphological changes during apoptosis
 
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
Liquid Biopsy Overview, Challenges and New Solutions: Liquid Biopsy Series Pa...
 
FNP workshop presentation
FNP workshop presentation FNP workshop presentation
FNP workshop presentation
 
Medicon 2016 presentation
Medicon 2016 presentationMedicon 2016 presentation
Medicon 2016 presentation
 
Automation in blood banking
Automation in blood bankingAutomation in blood banking
Automation in blood banking
 
Radar on rcc
Radar on rccRadar on rcc
Radar on rcc
 
Nrclinonc.2010.153
Nrclinonc.2010.153Nrclinonc.2010.153
Nrclinonc.2010.153
 

AUA Poster 2013-final

  • 1. ISOLATION AND ANALYSIS OF CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA AS ENABLED BY THE VERSA. E. Jason Abel, Jacob J. Tokar, Benjamin P. Casavant, Stephanie Thiede, Lindsay Strotman, David J. Beebe, Joshua M. Lang University of Wisconsin Carbone Cancer Center Acknowledgements Process Blood Collection Ficoll-Paque Density Centrifugation VERSA Isolation, Staining, and Imaging Clinical Data Blood from patients with metastatic clear cell carcinoma of the kidney were were drawn with a UW-IRB approved protocol and their CTCs were stained and analyzed for intact nuclei (DAPI), Carbonic Anhydrase IX and Cytokeratins. Single cells and cell clumps were identified from patient samples. Conclusions and Future Work Isolation and purification of RCC cells from peripheral blood using CAIX is possible using the VERSA platform. Ongoing studies will be aimed at identifying CTC heterogeneity, evaluation of DNA and RNA isolated from CTCs to provide evi- dence of their biologic potential in the metastatic cascade. Future studies will also investigate the potential of CTCs for prognostic indicators beyond methods of enumeration. Adhesion Invasion Metastases This work was supported by a grant from the Wisconsing Partnership Program and the DOD PCRP W81XWH-09-1-0192 Background Metastases, not primary tumors, are the most common cause for cancer pa- tient mortality. Circulating tumor cells are cells within the metastatic cas- cade that are accessible by a simple blood draw, and can act as a `liquid biopsy’for understanding tumor progression. Their enumeration has shown prognostic relevance, however methods to integrate analyses and take CTCs beyond enumeration have been limited. Intravasation and Transit Adhesion/Arrest Extravasation CTCs Abbreviations: PMP - Paramagnetic ParticleCTC - Circulating Tumor Cell PBMC - Peripheral Blood Mononuclear Cell The VERSA: Isolation: bead-bound cells of interest Non-target cells Magnet 2) Magnet pull 1) Add PMPs Vertical Exclusion Based Rare Sample Analysis Principle: Two aqueous solutions can be placed in adjacent wells, and due to the relative dominance of surface tension on the microscale, stay pinned, creating a‘vir- tual wall’at the interface. virtual wall Aqueous phases (cell suspensions, stains, washes) Oil phases INTRODUCTION AND OBJECTIVES: Circulating tumor cells (CTCs) have dem- onstrated prognostic ability in several cancers but similar studies in Renal Cell Carcinoma (RCC) are limited because the current techniques rely on positive selection of cells using cell surface markers rarely expressed in RCC cells. We have designed a novel platform to permit the use of any antibody of interest bound to paramagnetic particles (PMPs) to isolate and purify PMP-bound cells via immiscible oil barriers. The purpose of this study was to demonstrate and validate RCC cell isolation from blood by positive se- lection of cells expressing carbonic anhydrase nine (CAIX). METHODS: The Vertical Immiscible Filtration Assisted by Surface Tension (VerIFAST) platform was designed (BC, DB, patent filed) using the relative dominance of surface tension in the microscale to create virtual walls be- tween oil and aqueous phases filtering contaminants in a single step, while maintaining cell viability for further analysis. Initial experiments used samples of whole blood spiked with known RCC cell lines (786-0). After op- timization of technique and confirmation of capture, samples from patients with locally advanced and metastatic RCC were evaluated. RESULTS: Initial results demonstrate a high capture efficiency of the spiked 786-0 cells (~75% capture efficiency) and the ability to integrate intracellu- lar staining, with successful staining of both cytokeratins and the prolifera- tive marker, Ki-67. Patient CTCs were isolated and stained for intracellular cytokeratins for initial patient validation. CONCLUSIONS: Isolation and purification of RCC cells from peripheral blood using CAIX is possible using this novel platform. Further, the ability to perform intracellular analyses for therapeutic targets promotes the abil- ity of the VerIFAST to act as a liquid biopsy, informing clinical decision- making through analysis of cells directly within the metastatic cascade. On- ngoing studies with the VerIFAST will be aimed at identifying CTC heterog- eneity with the targets of cMet and mTOR, realizing the potential of CTCs for prognostic indicators beyond methods of enumeration Abstract Vertical Cell Isolation Vertical device orientation, featuring the long axis on the vertical instead of horizontal axis, allows non-target cells to passively settle out of the opera- tional path of the PMP-bound target cells FG FM Input Magnet Oil Traverses Wash Output 0 100 200 300 400 500 600 700 800 900 NumberofCells PBMC LNCaP Purity Traverse Number 1 2 3 77% 82% 86% 1 2 3 VERSA Device Side-View Force Vectors Cell Data This allows us to capture a few cells from a large background: 0 20 40 60 80 100 5M 20M 100M PercentRecovery Background PBMCs (M = million) One cell in 20M PBMCs target well Variable PBMCs PMP were bound to an antibody specific for Carbonic Anhydrase IX. The immortalized renal cancer cell line, 786-O, were incubated with CAIX-PMPs in the VERSA chip then captured as above. We show that capture efficiencies of 60-75% that is dependent on cell surface expres- sion of CAIX based on trypsiniza- tion versus gentle cell dissociation. Sieve-Assisted Staining A microporous membrane is fabricated into one of the VerIFAST wells such that fluid can be added and replaced from an adjacent well without touching the sample, critical for rare or delicate cell samples and enabling sophisticated flu- idic procedures in-device. Membrane Aspirate Add Fluid (Wash, Fixative, etc.) Incubate Repeatasnecessary Top View Side View Fluid Exchanges Rear Well Front Well Magnet PMP Removal 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1 2 3 4 5 Wash Number Normalized NumberofCells Loss Due to Washing 786-O Cells are then fixed, permeabilized, and stained with primary and secondary antibodies for extra and intracellular proteins Brightfield KI-67 Cytokeratins DAPI Merged MergedMerged DAPIDAPI Cytokeratins Total C-MET CA IX CA IX Total Nucleic Acid Extraction After imaging, cells are lysed with a RIPA buffer and PMPs bound to an oligo-dT are added to capture mRNA. An external magnetic force is applied and the PMP-mRNA conjugates are purified into the final rear well of the chip. A high salt buffer is then added to the sieve well to lyse nuclei. Silica beads are then added to bind DNA. An external magnetic force is applied and the PMP-DNA conjugates are purified into the final front well of the chip. Nucleic acids are eluted from PMPs in a 15uL volume and used for quantitative PCR for GAPDH and compared to a commercial Qiagen kit. 786-O cells were processed by the VERSA and mRNA extracted for gene expres- sion analysis of a housekeeping gene, P0, HIF1, HIF2, and FIH. Input Live Cell Staining Intracellular Staining DNA Purification mRNA Purification 1 10 100 1,000 10,000 100,000 1000 100 10 1 RelativeDNASignal Number of Cells Qiagen AllPrep VERSA 1 10 100 1,000 10,000 100,000 1000 100 10 1 RelativeRNASignal Number of Cells Qiagen AllPrep VERSA DAPI CKs CA IX Merged DAPI CKs CA IX Merged